{"id":544112,"date":"2021-05-20T22:22:01","date_gmt":"2021-05-20T22:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544112"},"modified":"2021-05-20T22:22:01","modified_gmt":"2021-05-20T22:22:01","slug":"age-related-vision-dysfunction-market-insight-epidemiology-and-market-forecast-analysis-report","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/age-related-vision-dysfunction-market-insight-epidemiology-and-market-forecast-analysis-report_544112.html","title":{"rendered":"Age Related Vision Dysfunction Market Insight, Epidemiology, and Market Forecast Analysis Report"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621498813.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Age Related Vision Dysfunction Market Insight, Epidemiology, and Market Forecast Analysis Report \" src=\"https:\/\/www.abnewswire.com\/uploads\/1621498813.jpeg\" alt=\"Age Related Vision Dysfunction Market Insight, Epidemiology, and Market Forecast Analysis Report \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Age-related Vision Dysfunction Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><strong>What is Age Related Vision Dysfunction?<\/strong><\/p>\n<p style=\"text-align: justify;\">Visual impairment in people as they age is among one of the most common and major health problems. With ageing, the human body goes through several changes; the normal functioning of the eye tissues gets hampered leading to vision loss.<\/p>\n<p style=\"text-align: justify;\"><strong>Age Related Vision Dysfunction Epidemiology<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per DelveInsight&rsquo;s epidemiological estimates, the United States reported maximum Age-related Vision Dysfunction prevalence, followed by&nbsp; Japan, Germany, Italy, France, the United Kingdom, with Spain contributing to the least Age-related Vision Dysfunction prevalence in 2020.<\/li>\n<li>The total Age-related Vision Dysfunction prevalent cases were 374,306,439 in the 7MM.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Age Related Vision Dysfunction Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">According to DelveInsight, the United States occupies the largest <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-vision-dysfunction-market\"><strong>Age-related Vision Dysfunction Market Share<\/strong><\/a>.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-vision-dysfunction-market\"><strong>Age-related Vision Dysfunction market research<\/strong><\/a> analyzes that the US takes up the maximum market share followed by Germany.&nbsp; Further, the United States Age-related Vision Dysfunction market share growth is expected to climb at a CAGR of 5.4% in the study period (2018&ndash;2030).<\/p>\n<p style=\"text-align: justify;\"><strong>Which biotechnological companies involved in the development of Age Related Vision Dysfunction therapies?<\/strong><\/p>\n<p style=\"text-align: justify;\">Key players energetically working in the domain include, Novartis, Allergan (AbbVie), Bayer, Santen, Regeneron Pharmaceuticals, Eyenovia, Genentech, Roche, Regenxbio, Graybug Vision, Aerpio Pharmaceuticals, Ocuphire Pharma, among several others.<\/p>\n<p style=\"text-align: justify;\">The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-vision-dysfunction-market\"><strong>Age-related Vision Dysfunction emerging therapies<\/strong><\/a>, which are under development are expected to offer a new paradigm in the treatment of Age-related Vision Dysfunction. Availability of alternative options (such as a novel therapeutic agent) to anti-VEGF treatment for the treatment is expected to offer patients several options.<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><span>1. Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Age-related Vision Dysfunction Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">3.1. Market Share (%) Distribution of Age-related Vision Dysfunction in 2018<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">3.2. Market Share (%) Distribution of Age-related Vision Dysfunction in 2030<\/p>\n<p style=\"text-align: justify;\"><span>4. Executive Summary of Age-related Vision Dysfunction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5. Epidemiology and Market Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6. Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.1. Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.2. Causes of Age-related Vision Dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">6.2.1. Age-related Macular Degeneration (AMD)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">6.2.2. Diabetic Retinopathy (DR)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">6.2.3. Cataract<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">6.2.4. Glaucoma<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">6.2.5. Presbyopia<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.3. Signs and symptoms of Age-related Vision Dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.4. Risk factors of Age-related Vision Dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.5. Pathophysiology of Age-related Vision Dysfunction<\/p>\n<p style=\"text-align: justify;\"><span>7. Diagnosis of Age-related Vision Dysfunction<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Patient History<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. Preliminary tests<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. Vision Acuity<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. Refraction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.5. Fundus Fluorescein Angiography (FFA)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.6. Indocyanine green angiography (ICG)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.7. Amsler Grid Test<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.8. Visual Field Test<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.9. Tonometry Test<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.10. Ophthalmoscopy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.11. Slit-lamp Examination<\/p>\n<p style=\"text-align: justify;\"><span>8. Prevention of Age-related Vision Dysfunction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Diagnostic Guidelines<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.1. American Family Physician guidelines<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.2. The National Institute for Clinical Excellence (NICE) &ndash; Diagnostic Guidelines for AMD<\/p>\n<p style=\"text-align: justify;\"><span>10. Current Treatment Practices: Age-related Vision Dysfunction<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.1. Treatments for advanced Diabetic Retinopathy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.2. Treatments for Cataract<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.3. Treatments for AMD<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.4. Treatments for Glaucoma<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.5. Treatments for Presbyopia<\/p>\n<p style=\"text-align: justify;\"><span>11. Treatment Guidelines<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1. American Family Physician Guidelines<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2. World Health Organization (WHO) Guidelines<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.3. Management Strategies for Correction of Presbyopia &ndash; The American Optometric Association<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.3.1. General Considerations<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.3.2. Patient Education<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.3.3. Prognosis and Follow-up<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.4. NICE guidance for corneal inlay implantation for correction of presbyopia<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.5. Management guidelines by the American Academy of Ophthalmology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.6. American Academy of Ophthalmology Guidelines for AMD<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.7. Guidelines of the Royal College of Ophthalmologists &ndash; Treatment of Neovascular AMD<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.8. The National Institute for Clinical Excellence (NICE) &ndash; Treatment Guidelines for AMD<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.8.1. Pharmacological management of AMD<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.8.2. Non-pharmacological management of AMD<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.9. American Academy of Ophthalmology &ndash; Guidelines for Diabetic Retinopathy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.10. International Council of Ophthalmology (ICO) &ndash; Guidelines for Diabetic Retinopathy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.11. International Council of Ophthalmology (ICO) &ndash; Guidelines for Cataract<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.12. International Council of Ophthalmology &ndash; Guidelines for AMD<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.13. American Academy of Ophthalmology &ndash; Guidelines for Cataract<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.14. American Academy of Ophthalmology &ndash; Guidelines for Glaucoma<\/p>\n<p style=\"text-align: justify;\"><span>12. Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2. Epidemiology of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.3. Epidemiology Scenario: 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.3.1. Total Prevalent Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.3.2. Total Diagnosed Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.3.3. Severity-specific Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.3.4. Total Treated Cases of Age-related vision dysfunction<\/p>\n<p style=\"text-align: justify;\"><span>13. The United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Total Prevalent Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2. Total Diagnosed Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3. Severity-specific Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.4. Total Treated Cases of Age-related vision dysfunction<\/p>\n<p style=\"text-align: justify;\"><span>14. EU-5<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.1. Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.1. Total Prevalent Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.2. Total Diagnosed Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.3. Severity-specific Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.4. Total Treated Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.2. France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.1. Total Prevalent Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.2. Total Diagnosed Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.3. Severity-specific Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.4. Total Treated Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.3. Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.1. Total Prevalent Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.2. Total Diagnosed Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.3. Severity-specific Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.3.4. Total Treated Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.4. Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.1. Total Prevalent Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.2. Total Diagnosed Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.3. Severity-specific Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.4.4. Total Treated Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.5. The United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.1. Total Prevalent Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.2. Total Diagnosed Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.3. Severity-specific Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.5.4. Total Treated Cases of Age-related vision dysfunction<\/p>\n<p style=\"text-align: justify;\"><span>15. Japan<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. Total Prevalent Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. Total Diagnosed Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3. Severity-specific Cases of Age-related vision dysfunction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4. Total Treated Cases of Age-related vision dysfunction<\/p>\n<p style=\"text-align: justify;\"><span>16. Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. Key Endpoints in Age-related Vision Dysfunction Clinical Trials<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Marketed Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.1. Rocklatan (Latanoprast; Netarsudil Dimesylate): Aerie Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.1.1. Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.1.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.1.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.1.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.2. Eybelis Ophthalmic Solution (DE-117, Omidenepag isopropyl): Santen Pharmaceutical\/Ube Industries<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.1. Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.2.5. Ongoing Current Pipeline Activity<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.3. Xelpros (Latanoprost Ophthalmic Emulsion): Sun Pharma Advanced Research Company Limited<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.3.1. Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.3.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.3.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.3.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.4. Rhopressa (Netarsudil mesylate): Aerie Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.4.5. Ongoing Current Pipeline Activity<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.5. Vyzulta (Latanoprostene Bunod Ophthalmic Solution): Bausch &amp; Lomb\/Nicox<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.5.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.5.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.5.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.5.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.6. Glanatec (Ripasudil hydrochloride hydrate): D Western Therapeutics Institute\/Kowa Pharmaceutical<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.6.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.6.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.6.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.6.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.7. Simbrinza (Brinzolamide\/Brimonidine Tartrate Ophthalmic Suspension): Novartis<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.7.1. Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.7.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.7.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.7.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.8. Tapcom\/DE-111 (Tafluprost\/Timolol Maleate; Taptiqom): Santen Pharmaceutical<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.8.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.8.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.8.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.8.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.8.5. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.9. Azarga\/Azorga (Brinzolamide\/Timolol): Novartis<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.9.1. Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.9.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.9.3. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.10. Combigan (Brimonidine\/timolol): Allergan (AbbVie)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.10.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.10.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.10.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.10.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.11. Lucentis (Ranibizumab): Genentech\/Novartis<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.11.1. Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.11.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.11.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.11.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.11.5. Ongoing Current Pipeline Activity<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.12. Eylea (Aflibercept): Bayer\/Regeneron Pharmaceuticals\/Santen<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.12.1. Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.12.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.12.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.12.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.12.5. Ongoing Current Pipeline Activity<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18.13. Beovu (Brolucizumab): Novartis<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.13.1. Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.13.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.13.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.13.4. Pivotal Clinical Trial<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">18.13.5. Ongoing Current Pipeline Activity<\/p>\n<p style=\"text-align: justify;\"><span>19. Emerging Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.1. AGN-190584: Allergan (acquired by AbbVie)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.1.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.1.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.1.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.1.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.2. MicroLine (Pilocarpine Ophthalmic): Eyenovia<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.2.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.3. PresbiDrops (CSF-1): Orasis Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.3.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.3.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.3.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.3.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.4. Zimura (Avacincaptad pegol): IVERIC Bio<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.4.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.4.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.4.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.4.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.5. ALK-001: Alkeus Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.5.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.5.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.5.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.6. ONS-5010\/Lytenava (Bevacizumab-vikg): Outlook Therapeutics<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.6.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.6.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.6.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.7. KSI-301: Kodiak Sciences<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.7.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.7.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.7.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.7.4. Safety and Eficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.8. Faricimab: Roche<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.8.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.8.2. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.8.3. Safety and Eficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.9. Abicipar: Allergan (AbbVie)\/Molecular Partners<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.9.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.9.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.9.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.9.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.10. RGX-314- Regenxbio<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.10.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.10.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.10.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.10.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.11. Beovu (RTH258; Brolucizumab): Novartis<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.11.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.11.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.11.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.11.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.12. STN1013001\/DE-130A (Catioprost; latanoprost emulsion): Santen SAS<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.12.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.12.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.12.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.13. NCX 470: Nicox Ophthalmics<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.13.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.13.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.13.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.13.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.14. OTX-TP (travoprost ophthalmic insert): Ocular Therapeutix<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.14.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.14.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.14.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.14.4. Safety and Eficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.15. PDP-716: Sun Pharma Advanced Research Company Limited<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.15.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.15.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.15.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.16. OPT-302: Opthea<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.16.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.16.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.16.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.16.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.17. Lumitin (Conbercept): Chengdu Kanghong Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.17.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.17.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.17.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.18. AKST4290 (Lazucirnon): Alkahest<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.18.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.18.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.18.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.19. GT005: Gyroscope Therapeutics<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.19.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.19.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.19.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.19.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.20. ADVM-022: Adverum Biotechnologies<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.20.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.20.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.20.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.20.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.21. Emixustat hydrochloride (emixustat): Kubota Vision<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.21.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.21.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.21.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.21.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.22. KVD001: KalVista Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.22.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.22.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.22.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.22.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.23. Luminate (ALG-1001, Risuteganib): Allergo Opthalmics\/Baush Health<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.23.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.23.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.23.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.23.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.24. GB-102: Graybug Vision<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.24.1. Product Descritpion<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.24.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.24.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.24.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.25. Razuprotafib (AKB-9778): Aerpio Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.25.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.25.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.25.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.25.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.26. Nyxol (Phentolamine Mesylate): Ocuphire Pharma<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.26.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.26.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.26.3. Clinical Development<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.27. STN1012600 (DE-126): Santen Pharmaceutical<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.27.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.27.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.27.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.27.4. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>20. Age-related Vision Dysfunction: 7 Major Market Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2. Market Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.3. 7MM Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.3.1. Total Market Size of Age-related Vision Dysfunction in the 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20.3.2. Market Size of Age-related Vision Dysfunction by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\"><span>21. The United States Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.1. Total Market Size of Age-related Vision Dysfunction in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.2. Market Size of Age-related Vision Dysfunction by Therapies in the United States<\/p>\n<p style=\"text-align: justify;\"><span>22. EU-5 Market Size<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22.1. Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.1. Total Market size of Age-related Vision Dysfunction in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.2. Market Size of Age-related Vision Dysfunction by Therapies in Germany<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22.2. France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.2.1. Total Market size of Age-related Vision Dysfunction in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.2.2. Market Size of Age-related Vision Dysfunction by Therapies in France<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22.3. Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.3.1. Total Market size of Age-related Vision Dysfunction in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.3.2. Market Size of Age-related Vision Dysfunction by Therapies in Italy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22.4. Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.4.1. Total Market size of Age-related Vision Dysfunction in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.4.2. Market Size of Age-related Vision Dysfunction by Therapies in Spain<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22.5. The United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.5.1. Total Market size of Age-related Vision Dysfunction in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.5.2. Market Size of Age-related Vision Dysfunction by Therapies in the United Kingdom<\/p>\n<p style=\"text-align: justify;\"><span>23. Japan<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">23.1. Total Market size of Age-related Vision Dysfunction in Japan<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">23.2. Market Size of Age-related Vision Dysfunction by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\"><span>24. Market Access and Reimbursement<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.1. Key HTA decisions for Age-related Vision Dysfunction<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.1.1. AMD<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.1.2. Glaucoma<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.1.3. Diabetic Retinopathy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.1.4. Cataract Surgery<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.1.5. Presbyopia<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.2. Patient Access Programs<\/p>\n<p style=\"text-align: justify;\"><span>25. Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>26. Market Barriers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>27. SWOT Analysis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>28. Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>29. Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">29.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">29.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><span>30. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>31. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>32. About DelveInsight<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Request sample pages for more information on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/age-related-vision-dysfunction-markethttps:\/www.delveinsight.com\/sample-request\/anorexia-market\">Age Related Vision Dysfunction Market Size<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=age-related-vision-dysfunction-market-insight-epidemiology-and-market-forecast-analysis-report\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=age-related-vision-dysfunction-market-insight-epidemiology-and-market-forecast-analysis-report\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Age-related Vision Dysfunction Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/age-related-vision-dysfunction-market-insight-epidemiology-and-market-forecast-analysis-report_544112.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-544112","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544112"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544112\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}